T he need for adequate caloric intake, weight gain, and body fat for the progression of growth and puberty is well documented. In children, starvation or illness is associated with a decreased growth rate, whereas recovery or refeeding results in accelerated linear growth, often referred to as "catch-up" growth. [1] [2] [3] However, to the best of our knowledge, there are no recent systematized studies concerning the effect of undernutrition during puberty on growth rate and final adult height.
Animal experiments have shown that if growth is slowed for prolonged periods or into puberty, then complete catch-up (ie, attainment of expected final height) is not achieved. 1 Findings in humans are less consistent, however. Acheson 4 claimed that complete catch-up growth is not achieved because during starvation, skeletal maturation is not slowed down as much as linear growth. By contrast, Prader and Tanner 1 and Lacey et al 5 found that the rate of bone-age progression during the recovery phase may be lower than the rate of linear growth catch-up, so the final relation of height to bone age may return to normal.
Anorexia nervosa (AN), characterized by a significant reduction in current or expected weight; refusal to gain weight; amenorrhea; and a disturbance in body image, overvalued importance of weight for self-esteem, or denial of the severity of weight reduction, 6 represents a ready group for studying the effect of caloric restriction during adolescence on growth. There have been several reports of AN 7, 8 or other forms of voluntary caloric restriction 9, 10 presenting as growth failure or short stature. Reports regarding catch-up growth range from failure to gain any height 7 to complete catch-up growth. 2, 7, 9 This apparent discrepancy reflects small patient series, heterogeneous patient populations, variable duration of follow-up, and absence of premorbid growth data.
Several hormonal changes may contribute to growth retardation in AN. These include low thyroxine (T 4 ) and triiodothyronine (T 3 ), elevated cortisol, and low sex hormone levels. [11] [12] [13] Growth hormone resistance-characterized by growth hormone hypersecretion and low serum levels of growth hormone-binding protein, insulin-like growth factor I, and insulin-like growth factor-binding protein 3-has also been related to growth failure in patients with AN. 14, 15 Although AN affects mainly the female gender, approximately 10% of the patients are male, and the incidence of the disorder in male individuals has increased in recent years. 11, 13, 16 The effect of malnutrition and the amount of catch-up growth after correction of malnutrition may be different in male compared with female adolescents, reflecting the longer duration of bone growth in male individuals and their higher caloric requirements. However, the exact nature of this difference is inconsistent. Some studies have found that undernourishment may result in a significant stunting of growth in male adolescents 2, 17 but has only a marginal effect in female adolescents. 16, 18 Other investigators have noticed advanced skeletal maturation during growth retardation, resulting in permanent foreshortening, in a female patient but not in male patients. 7 These differences may be related to the small numbers of patients investigated or the comparison of final to nonfinal heights. The aim of the present study was to assess growth retardation in male patients with AN and the effect of weight restoration on catch-up growth. The following were our hypotheses: 1) most male patients with AN would show significant growth retardation on admission to inpatient treatment; and 2) although weight restoration would be associated with a significant catch-up growth, most male patients with AN would not attain their expected height.
METHODS

Patients
The medical records of all male patients who had AN (n ϭ 12) and were hospitalized in the Pediatric Psychosomatic Department of the Sheba Medical Center, Tel Hashomer, Israel, from January 1, 1994, to December 31, 1998 19 according to the criteria of the DSM-IV. 6 Although 4 of the patients (patients 3, 5, 11, and 12) did not meet weight criteria for AN at the time of the initial hospitalization in our institution, all of them did so at some time in the course of their illness. None of the patients had evidence of bulimia nervosa, an organic brain disorder, schizophrenic-spectrum disorders, substance abuse disorders, or any significant medical or neurologic disorder, including those with the potential to affect food consumption and weight (eg, diabetes, primary thyroid disorders, renal disorders). None of the patients received any medication before or in the first month of hospitalization. However, several patients received antidepressant agents or mood stabilizers during consecutive treatment. These medications may affect appetite, weight, or endocrine function but to the best of our knowledge do not significantly influence linear growth. 20 
Setting
The Chaim Sheba Medical Center is a tertiary care center with the Pediatric Psychosomatic Department serving as a nationwide referral center. Patients are referred for hospitalization after outpatient or other inpatient treatment has failed. Treatment is based on behavioral rehabilitation of disordered eating performed by a multiprofessional team and provision of individual, family, and group psychotherapy.
Height and Weight Measurements
The standing height was measured to the nearest 0.1 cm, using a wall-mounted stadiometer. For the sake of reducing internal variability, all measurements were taken during the morning hours, single handedly, by a single investigator (A.T.), using standardized procedures, as suggested by Tanner. 21 Body weight was obtained to the nearest 0.1 kg, with the patient wearing a hospital gown and without any footwear.
Premorbid height and weight measurements were obtained for each case from the primary care physician and/or the school nurse. Height and weight measurements were obtained at admission. Thereafter, during hospitalization, weight was obtained weekly and height was obtained monthly. During the outpatient follow-up period, height and weight were obtained at every visit, according to a schedule outlined below. For the purpose of analysis, only height measurements taken at least 3 months apart were considered.
Standard deviation scores (SDS), or z scores, for height and weight were calculated on the basis of data on growth in a reference population from the National Center for Health Statistics (Centers for Disease Control and Prevention, Atlanta, GA). The use of SDS for growth status allows for comparison of data obtained at different ages. A z score of 0 corresponds to the 50th percentile, and a z score of Ϫ1.0 indicates 1 SD below the mean, which corresponds to approximately the 15th percentile of the reference population.
Percent of height-appropriate body weight was calculated as measured weight Ϭ ideal body weight (IBW) ϫ 100, where IBW was defined as the 50th percentile weight corresponding to the age at which the child's height was the 50th percentile height. 22 The midparental target height was calculated from the average of the parents' heights, plus 6.55 cm. 23 
Management
After assessment of the nutritional status, a nutritional rehabilitation program is constructed. This program is geared toward a weight gain of 0.5 to 1.0 kg/wk. Target weight is established according to age and the estimated potential height, which is based on the premorbid height SDS.
Patients are discharged on reaching their target weight and maintaining it for at least 2 weeks. After discharge, patients are followed every 2 weeks during the first 2 months, once a month during the next 4 months, and every 3 months thereafter until they have reached the age of 18. In patients who have not finished growing, target weight is readjusted every 3 months during the follow-up period and is increased gradually to allow for the expected height gain, based on the potential height. Patients who terminate their regular follow-up before the age of 18 are invited for a final evaluation around that age.
Data Analysis
Height and weight parameters at admission and at last follow-up were compared using the paired Wilcoxon test. Patients who had growth deceleration before admission were evaluated against the other patients by comparing the distributions in the 2 groups with the Wilcoxon test for independent samples.
To examine the relation of height gain to weight gain, we analyzed the growth data of patients with evidence of growth failure either before hospitalization or during follow-up. Lineargrowth rate (cm/y) and weight-gain rate (kg/y) were calculated for each time fragment between 2 serial measurements for each of these patients. We divided the resulting 36 time fragments available into 2 subgroups according to the weight gain being Ͼ1 kg/y or Յ1 kg/y. According to the National Center for Health Statistics growth curves, a weight gain of Ͻ2 kg/y is below the third percentile for all growing children. The 1 kg/y cutoff point, therefore, represents a particularly strict criterion for failure to gain weight. The relationship between linear growth and weight changes was estimated using Spearman's nonparametric correlation coefficients in each group. The Wilcoxon test for independent samples was used to compare the average changes in the 2 groups. Results were considered as significant when the 2-sided P value was Ͻ .05. Calculations were performed using the SAS 6.12 for Windows software (SAS, Inc, Cary, NC).
RESULTS
Patient Characteristics
The pertinent admission and follow-up data of the 12 patients are summarized in Table 1 . The mean age at admission was 14.3 Ϯ 1.6 years (range: 11.7-16.6 years). The mean reported duration of symptoms before hospitalization was 12.4 Ϯ 11.1 months (range: 3-42 months). Mean duration of follow-up was 38.8 Ϯ 19.4 months (range: 9 -78 months). All patients who terminated their regular follow-up before the age of 18 were invited for a final evaluation around that age. Three patients were hospitalized in other institutions before their admission to our department, and 5 patients had recurrent admissions to our facility during the follow-up period because of relapse of their eating disorder. The mothers of 2 of the patients had a history of AN.
Weight
Premorbidly, patients tended to be slightly overweight, their weight being 108 Ϯ 8% of their IBW. Three patients (patients 2, 5, and 7) were overweight (weight Ͼ120% of IBW). At the time of admission, the mean weight was significantly (P Ͻ .01) reduced, 83.5 Ϯ 5.9% of the IBW, and the mean body mass index was 15.7 Ϯ 1.3 kg/m 2 (range: 13.5-18 kg/m 2 ). The weight of 4 of the patients (patients 3, 5, 11, and 12) was not below 85% of IBW at the time of admission (Table 1) . However, all of these patients did weigh below 85% of IBW during a different period of their disease (legend to Table 1) ; thus, all patients fulfilled the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition diagnostic weight criterion for AN. At the end of follow-up, the weight of all patients improved significantly: the mean weight increased to 102.1 Ϯ 8.6% of IBW (P Ͻ .001), and the mean body mass index increased to 20.1 Ϯ 1.4 kg/m 2 (P Ͻ .001). Weight percent-of-IBW at the end of follow-up was not significantly different from the premorbid weight.
Linear Growth
The mean premorbid height SDS was Ϫ0.21 Ϯ 0.91. At the time of admission, the mean height SDS was significantly lower, Ϫ0.81 Ϯ 0.93 (P ϭ .008).
Ten of the 12 patients exhibited growth retardation at the time of admission, as evident in a decrease in height SDS at admission, compared with the premorbid height SDS. One patient (patient 2) had evidence of stunted growth 3.5 years before admission, and 3 other patients (patients 4, 7, and 12) exhibited growth retardation at least 1.5 years before hospitalization (Fig 1) . In 1 of the 2 patients (patient 3) who did not show growth failure at admission (the other one being patient 6), a markedly decreased linear growth was observed during the follow-up period, before weight restoration. Weight restoration resulted in accelerated linear growth (up to a rate of 16 cm/y) in all patients with growth retardation. In some patients, a "staircase" pattern of growth was observed, ie, rapid weight restoration during hospitalization resulting in accelerated height gain, alternating with growth arrest during periods of weight loss or failure to attain or maintain target weight (Fig 1A) .
To define further the relationship between height gain and weight gain, we correlated the changes in height to changes in weight during the intervals between serial height and weight measurements. Only measurements taken at least 3 months apart were considered for this analysis. Thirty-six time fragments were found for the patients with growth retardation. Positive weight gain (weight gain rate Ͼ1 kg/y) was associated with a mean height gain of 6.97 Ϯ 6.48 cm/y, whereas weight loss or failure to NA indicates not applicable. * The "admission" data in the table reflect (for reasons of standardization) the height and weight measurements at the time of the first admission to our department, which does not necessarily coincide with the lowest weight-for-height in the course of the disease. Because of this, the weights of patients 3, 5, 11, and 12 seem not to fulfill the DSM-IV diagnostic criteria for AN of refusal to maintain body weight at or above 85% of that expected. Patient 3 met the formal weight criteria for AN later in the course of his illness (worst height-for-weight: age 16.5 years; height: 160 cm; weight: 40 kg; weight-for-height: 82.5% of IBW). Patient 5 was premorbidly obese and had lost 25% of his body weight during the 2 years preceding his admission. At the time of hospitalization, his weight was at 88% of his IBW, but later during his follow-up he met the formal criteria for AN (worst height-for-weight: age 15 10/12 years; height: 176 cm; weight: 56.2 kg; weight-for-height: 84.5% of IBW). Patient 11 was treated in another institution before his admission to our department and thus met the formal criteria for the diagnosis of AN before he presented to our institution (at age 11 8/12 years; height: 145 cm; weight: 31 kg; weight-for-height: 83.8%). Patient 12 had virtually no linear growth during the 2 years preceding his admission, with his height decreasing from the 95th percentile to the third percentile. Thus, his apparent "adequate" weight-for-height at the time of admission actually reflects stunting of growth (see also Fig 1B) .
gain weight (weight gain rate Յ1 kg/y) was associated with minimal height gain-only 2.7 Ϯ 3.86 cm/y (P Ͻ .015; Fig 2) . Correlation analysis revealed a significant positive correlation between weight gain and height gain in the positive weight gain group (weight gain rate Ͼ1 kg/y; r ϭ 0.44, P Ͻ .04) but not in the negative weight gain group.
Final Height Data
Final height (defined as height at age 17 or older and no linear growth for at least 1 year) was measured by us in 8 of the patients. For the other 4 patients, who terminated their follow-up before the age of 18 and refused to be reevaluated in our facility, final height was measured using a wall-mounted stadiometer in the primary care clinic and reported to us by the patients and parents. Table 1 indicates that despite the growth acceleration after weight restoration, only 2 of the 11 patients with growth retardation (patients 1 and 7) achieved complete catch-up growth (ie, a final height SDS equal to or greater than their premorbid height SDS). The mean final height SDS was Ϫ0.52 Ϯ 0.84, whereas the mean midparental target height SDS was Ϫ0.21 Ϯ 0.79. Thus, final height SDS tended to be lower than both the premorbid SDS (Ϫ0.21 Ϯ 0.91) and the target height and higher than the admission SDS (Ϫ0.81 Ϯ 0.93), although the differences did not reach statistical significance (see Fig 3 for the differences between final height and target height). When the patients who were not measured in our facility were excluded, the mean final height SDS for the other 8 patients was Ϫ0.71 Ϯ 0.96.
DISCUSSION
The aim of the present study was to assess growth retardation and its correction after weight restoration in male patients with AN. The mean premorbid height SDS of the 12 patients was Ϫ0.21 Ϯ 0.91, similar to the expected height SDS in a normal population. The mean premorbid weight, however, was 108 Ϯ 8% of the IBW. Furthermore, some of our patients were overweight (weight Ͼ120% of IBW), consistent with previous reports of male patients with AN. 24, 25 The results of the present study support both of our hypotheses. Growth failure was a prominent feature in our group of male adolescent inpatients with AN, appearing in 11 of 12 patients. In 10 of these patients, it was already evident at the time of hospitalization, and 1 other patient exhibited growth retardation in the early stages of treatment, before weight gain. Moreover, decreased linear growth preceded the reported onset of symptoms by 1.5 to 3.5
Fig 1. Growth curves of patients 2 (A) and 12 (B)
. Note that growth failure ("shifting" of height percentiles) was evident up to 3.5 years before the time when symptoms were first noted. A, A "staircase" pattern of growth is observed. B, The weight of this patient was at the 95th percentile at 9 years of age and had shifted to the third percentile during the 2 years before hospitalization. He had virtually no linear growth during the 2 years preceding his admission, with his height decreasing from the 95th percentile to the third percentile. Thus, his apparent "adequate" weight-for-height at the time of admission reflects delayed diagnosis and stunting. Growth deceleration may not have been noted because height was at or above the 50th percentile and the patient was probably still perceived as normal compared with his peers.
years in a third of our sample. These findings propose that early signs of AN may not be detected in a significant number of male patients with AN, delaying the diagnosis of the disorder.
Weight restoration resulted in accelerated linear growth (up to 2 cm/mo) in all patients with growth retardation. Despite this robust correction of growth failure, complete catch-up growth was not achieved: mean final height SDS of our patients tended to be lower than both the premorbid height SDS and the target height SDS, and only 2 of the 11 patients with growth failure achieved complete catch-up growth (ie, a final height SDS equal to or greater than their premorbid height SDS).
Our results emphasize the utmost importance of a relentless effort to pursue and maintain the target weight of male patients with AN for the restoration of height to the premorbid percentile for age. This is evident in the significant association in our sample of positive weight gain with positive mean height gain and of weight loss or failure to gain weight with minimal height gain. The existence of a significant correlation of weight gain and height gain only in the positive weight gain group lends additional support to this requirement. In a healthy growing child or adolescent or during catch-up growth, a strong correlation between height gain and weight gain is the rule. However, because negative height gain is not possible, different degrees of weight loss all may result in a similar degree of growth failure (ie, lack of linear growth) as evident in the lack of correlation between weight gain and height gain in the negative weight gain group.
The inability to achieve complete catch-up growth in most of our patients further indicates that a weight restoration program geared at restitution of height to the premorbid percentile for age should be initiated as early as possible in the treatment of male adolescents with AN. 26 Acceptance of weight as appropriate for height as measured at admission, with no consideration of the premorbid or potential height, may result in perpetuation of growth retardation, leading eventually to short stature.
Previous studies have claimed growth retardation to be an important feature of AN, 7, 8 with weight restoration resulting in catch-up growth in many patients. 2, 7, 8 However, it has not been established yet whether the growth retardation seen in AN affects final adult height. In the single study that previously addressed this issue, 2 final adult heights of 71 patients with AN (13 male and 58 female) were reported. These authors alleged that most patients reached their expected heights. However, the final height percentile was compared with the height percentile at diagnosis, and no reference was made to premorbid height percentiles. Moreover, because only limited information was given regarding the age distribution of this group, it is possible that at least some of the patients had already completed most of their growth before the onset of their illness. Siegel et al 27 reported a higher-than-expected incidence of short stature among 10 male patients with AN, but no reference to growth rate or patterns was made. By contrast, our data suggest that the stunted stature of the patients at the end of follow-up (ie, final height SDS Ϫ0.52 Ϯ 0.84) is the result of pro-longed malnutrition and not related to premorbid short stature (premorbid height SDS: Ϫ0.21 Ϯ 0.91).
It is important to consider why some of our patients apparently sought medical attention relatively late in the course of their eating disturbance. Lack of awareness of AN in male individuals may be 1 factor that leads to a delay in diagnosis. We further propose that because of the baseline high caloric requirements of male adolescents, decreased caloric intake may go unnoticed for a significant period of time. In addition, weight loss in our patients may have been masked by their reduced height, present already before admission. Finally, growth failure may not be recognized in adolescents whose heights are in the upper percentiles. For instance, 1 patient (patient 12) shifted from the 95th to the 50th height percentile before AN was noticed, perhaps because he was still perceived as normal relative to his peers (Fig 1B) .
Whatever the reason, a delay in the diagnosis of AN in male adolescents may result in severe malnutrition and compromised height. Therefore, the diagnosis of AN should be considered in short, underweight adolescents, as well as in youths who demonstrate growth deceleration with hitherto normal height progression. Obtaining a detailed history of caloric intake, attitude to food, body image, and sports participation in such patients may facilitate earlier diagnosis of AN. As the incidence of AN is increasing and the age of onset is decreasing, 11, 16 the need for prompt evaluation and treatment becomes even more important.
Our series includes 12 patients, which makes it 1 of the largest series describing growth in male patients with AN, and it provides important premorbid and follow-up data as well as final-height data not provided by other series. One possible limitation of our study concerns the reliability of premorbid height, measured by the school nurse. It should nevertheless be noted that in Israel, school nurses are certified public health nurses trained in obtaining anthropometric measurements, and inspection of the growth curves revealed good consistency between different measurements of each patient.
Another limitation of our study is that Tanner stages of sexual development and results of endocrine function tests were not recorded in most of the charts. Therefore, we were unable to investigate the relationships among pubertal stages, onset of AN, Comparison of premorbid height to height at the time of admission, final height, and the midparental target height. Height is expressed in z scores at all time points. E, Individual patients; F, mean Ϯ standard deviation for the whole group. The mean height z score At the time of admission was significantly lower than the premorbid height z score. The final height z score was lower than both the premorbid and the target height z scores and higher than the admission z score.
and adult height or to calculate the premorbid predicted adult height. Some may argue that the growth deceleration and subsequent catch-up growth observed in our patients represent the effects of delayed puberty per se. However, close inspection of the growth data precludes this possibility. First, the severity of growth failure observed in some of our patients far exceeds the prepubertal growth deceleration observed in children with delayed puberty, which is in the range of 4.0 to 4.5 cm/y. 28, 29 For instance, patient 12 had virtually no linear growth for the 2 years preceding his hospitalization (Fig 1B) . Indeed, as depicted in Fig 2, linear growth rate was 2 cm/y or less during 13 of all 16 time fragments that represent the periods of failure to gain weight of all patients investigated. Second, the "staircase" pattern of growth exhibited by some of our patients, ie, periods of accelerated height gain intersected by periods of growth arrest during weight loss or failure to attain or maintain target weight (Fig 1A) , is not consistent with a normal pubertal growth spurt. Finally, although patients with delayed puberty may not reach their parental target height, 30,31 they typically regain or even exceed their own childhood growth percentile. 32 In contrast, in our patients, catch-up growth was incomplete, and their premorbid height percentile was not reached.
CONCLUSION
Our findings support the importance of growth retardation in male adolescent patients with AN. For achieving maximal catch-up growth, premorbid growth data should be obtained, and target weight should be based on the expected rather than the measured height percentile at the time of diagnosis. Larger scale prospective linear studies, which will include sexual maturation evaluation as well as endocrine studies, are required to verify our observations and to define further the factors that influence the final height and the optimal therapeutic approach for optimizing catch-up growth in male adolescents with AN.
